Myriad’s Ovarian Cancer Portfolio Helps Personalize Each Patient’s Treatment

Ovarian Cancer Portfolio

BRACAnalysisCDx

Treatment Decision: Lynparza® (olaparib) treatment for patients with breast or ovarian cancer. Zejula® (niraparib) maintence therapy for patients with ovarian cancer.1,2,3
Assay: Full gene sequencing and large rearrangement analysis of BRCA1 and BRCA2
Sample Type: Blood
Mutations Identified: Germline (in every cell of the body)
Myriad myRisk

Treatment Decision: PARP inhibitors*, DNA-damaging chemotherapy, family implications
Assay: Full gene sequencing and large rearrangement analysis of BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, CDKN2A, CDK4, TP53, PTEN, STK11, CDH1, BMPR1A, SMAD4, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD51C, RAD51D, POLD1, POLE, GREM1
Sample Type: Blood/Saliva
Mutations Identified: Germline (in every cell of the body)
Myriad myChoice HRD

Treatment Decision: PARP inhibitors*, DNA-damaging chemotherapy
Assay: Tumor BRCA1 and BRCA2 assessment, Genomic Instability Status to determine whether homologous recombination deficiency is present in the tumor
Sample Type: Tumor (FFPE)
Mutations Identified: Tumor mutations (inclusive of germline and somatic)†
BRACAnalysis

Treatment Decision: PARP inhibitors*, DNA-damaging chemotherapy, family implications
Assay: Full gene sequencing and large rearrangement analysis of BRCA1 and BRCA2
Sample Type: Blood/Buccal
Mutations Identified: Germline (in every cell of the body)


*BRACAnalysis CDx has been approved by the FDA for patients with breast and ovarian cancer who are or may become eligible for treatment with the PARP inhibitor Lynparza® (olaparib). BRACAnalysis CDx can also identify patients with ovarian cancer who may experience enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. myRisk, myChoice HRD and BRACAnalysis have not been reviewed or approved by the FDA.1,2

†Follow-up testing on a blood or saliva sample is recommended to determine whether a tumor BRCA1/2 mutation is germline (inherited) or somatic (isolated to the tumor).

Ovarian Cancer Publications

In the SOLO2 trial, a significant improvement in progression-free survival was observed in patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer when treated with the PARP inhibitor olaparib. Also, other studies such as Study 19, ARIEL2, and NOVA demonstrated that an assessment of homologous recombination deficiency (HRD) in addition to BRCA1/2 status can predict which patients are likely to experience a greater magnitude of benefit from PARP inhibitor therapy. Explore these publications to learn more about how BRCA1/2 and HRD testing can impact treatment decisions related to PARP inhibitor therapy and DNA-damaging chemotherapy in ovarian cancer.

How Does Testing Impact Treatment Decisions Related to PARP Inhibitors and DNA Damaging Agents?

What is the difference between a germline and a somatic mutation?

Sources:
  1. Intended Use: BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.

    Results of the test are used as an aid in identifying breast and ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants, who are or may become eligible for treatment with Lynparza® (olaparib). Detection of deleterious or suspected deleterious germline BRCA variants by the BRACAnalysis CDx test in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. This assay is for professional use only and is to be performed only at 320 Wakara Way, Salt Lake City, UT 84108.
  2. For more detailed information about Lynparza and its safety and efficacy please go to lynparza.com
  3. For more detailed information about Zejula and its safety and efficacy please go to zejula.com
  4. Alsop, K. et al. (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol., 30, 2654–2663.
Lynparza is a registered trademark of the AstraZeneca group of companies. Zejula is a registered trademark of Tesaro, Inc.